<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30026423</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>12</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">0385-0684</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>45</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jun</Month>                    </PubDate>                </JournalIssue>                <Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>                <ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>            </Journal>            <ArticleTitle>[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].</ArticleTitle>            <Pagination>                <MedlinePgn>965-968</MedlinePgn>            </Pagination>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">There are many reports that describe the effectiveness of aromatase inhibitors as endocrine therapy after breast cancer surgery. However, there are few detailed evaluations of patient adherence to anastrozole(ANA)therapy. Here, we evaluated the adherence to ANA therapy in postoperative patients with primary breast cancer.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We investigated 102 postoperative patients with primary breast cancer without distant metastasis, who received ANA at JCHO Kyusyu Hospital. We calculated the medication continuation rate and disease-free survival at 5 years from the initiation of medication. The reasons for medication discontinuation and alternative drug therapy after ANA therapy discontinuation were also investigated. Re- sults: The 5-year continuation rate of ANA treatment alone was 79%(81/102). The rate of all patients who continued ANA treatment, including 9 who changed to other drugs, was 88%(90/102). The most frequent ANA discontinuation reasons were progressive disease(8 cases), arthritis(5 cases), and nausea(3 cases). The disease-free survival rate was 92%(94/102), and the overall survival rate was 97%(99/102).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ANA showed a high continuation rate. Adherence of ANA in postoperative patients with breast cancer was well maintained, even when the treatment was changed to other drugs due to adverse events.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ogasa</LastName>                    <ForeName>Yuto</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Dept. of Pharmacy, Japan Community Health Care Organization Kyushu Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kuwamura</LastName>                    <ForeName>Tsuneo</ForeName>                    <Initials>T</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Akiyoshi</LastName>                    <ForeName>Takao</ForeName>                    <Initials>T</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Murakami</LastName>                    <ForeName>Soichiro</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Tanaka</LastName>                    <ForeName>Haruo</ForeName>                    <Initials>H</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Umeda</LastName>                    <ForeName>Shuyo</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Suematsu</LastName>                    <ForeName>Fumihiro</ForeName>                    <Initials>F</Initials>                </Author>            </AuthorList>            <Language>jpn</Language>            <PublicationTypeList>                <PublicationType UI="D023362">Evaluation Studies</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Japan</Country>            <MedlineTA>Gan To Kagaku Ryoho</MedlineTA>            <NlmUniqueID>7810034</NlmUniqueID>            <ISSNLinking>0385-0684</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>2Z07MYW1AZ</RegistryNumber>                <NameOfSubstance UI="C090450">anastrozole</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30026423</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>